Marabelle highlighted that the prognostic value of biomarkers is treatment-dependent, citing the Philadelphia chromosome as a poor prognostic marker for leukemia before imatinib became available, but a key therapeutic target after. #SITC25 bit.ly/3LLunuM

Moran Amit finished his #SITC25 talk by summarizing that nerve injury, often caused by perineural invasion, drives an immunosuppressive microenvironment, causing resistance to anti-PD-1. bit.ly/3LLunuM

In the Nov. Issue of the #JITC Digest, Editor-in-Chief Dr. Michael T. Lotze reflects on his experience at #SITC25 and several recent IO meetings. Explore his curated selection of cutting-edge articles, including new insights on LAG-3 blockade and more. View the Nov. Issue: https://ow.ly/fTO150Xun1R

Our #SITC25 recap is out today!
Check out the standout presentations and insights from top institutions and speakers: bit.ly/3LLunuM.

MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting | OncLive Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting @mdanderson.bsky.social @sitcancer.bsky.social #SITC25 #oncology
www.onclive.com/view/md-ande...

Explore the latest discoveries in #cancer #immunology and #immunotherapy published in JEM. This collection covers a broad range of topics, including T cell biology, immune checkpoint inhibitor therapies, and signaling pathways involved in antitumor immunity. 👉 rupress.org/jem/collecti...

#SITC25

Our work was highlighted by @jguerriero.bsky.social at #SITC25 today, session "Cellular Therapies for Solid Tumors, Cell Therapies beyond CAR T Cells." Check out the pre-print on BioRxiv! @sitcancer.bsky.social @sgholamin.bsky.social @nebanovich.bsky.social

Students from the D.C. area connect with local mentors to learn about immunotherapy and the various potential career paths within the field. Special thanks to organizers Drs. Chelsea C. Pinnix, Avery Posey and our Workforce Development Committee.

#SITC25 Undergrads in STEM Program.

Xiaofei Yu and colleagues uncover MCRS1 as a new activator of major histocompatibility complex (MHC) class I, which elicits anti-tumor immunity and enhances anti-PD-1 therapy. rupress.org/jem/article/...

📘 In #cancer #immunotherapy collection: rupress.org/jem/collecti...

#SITC25

Wen et al. review how YTHDF proteins regulate tumor responses to #radiotherapy by modulating DNA repair & the immune microenvironment, and discuss their potential as therapeutic targets. rupress.org/jem/article/...

📘 In #cancer #immunotherapy collection: rupress.org/jem/collecti...
#SITC25

Are you using the right tumor micro environment model? Cancer is a disease of aging @sitcancer.bsky.social #SITC25 great session at the annual meeting on the aged immune system and the tumor micro environment moderated by Drs DA and A Weeraratna.

Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.

This technology will expand access to solid tumor cell therapy 🌟

Arja Ray, @maxkrummel.bsky.social et al. show that targeting CD206⁺ #macrophages disrupts the establishment of a key antitumor immune axis. rupress.org/jem/article/...

📘 In #cancer #immunotherapy collection: rupress.org/jem/collecti...

#SITC25

Beautiful talk from Sohail Tavazoie at #SITC25! The intersection between neuroscience and cancer is fascinating, and particularly enjoyed the reminder that nerves in cancer were identified in @jem.org in 1897! 🧐 #JEMlegacy rupress.org/jem/article-...

#SITC25: Akeso, Summit’s PD-1xVEGF drug extends life in China lung cancer study Researchers reported that adding Akeso and Summit Therapeutics’ ivonescimab to chemotherapy cut the risk of death by 26% in a study conducted in China for a certain form of lung cancer. The study, known as ...

Signal or noise? > #SITC25: Akeso, Summit’s PD-1xVEGF drug extends life in
China lung cancer study >> Comment below! #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical

Thanks for everyone who joined the #SITCFunRun and kicked off their day with fresh air and great views! Let's keep the energy going! #SITC25

What a fantastic opportunity to share our work! Thank you organizers for a great pre-conference event at #SITC25
Looking forward to even more awesome science in the days to come!

MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting As immunotherapy continues to transform cancer care, researchers at The University of Texas MD Anderson Cancer Center are sharing new insights at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting about how the immune system can be trained, guided and strengthened to improve patient outcomes. MD Anderson scientists and clinicians will present nearly 30 abstracts and lectures at this year's meeting. Below is a selection of key questions that will be addressed in oral abstracts and presentations.

Our researchers will share insights at #SITC25 about how the immune system can be trained, guided and strengthened to improve patient outcomes.

More about the nearly 30 abstracts and lectures presented at this year’s meeting: spr.ly/60147PkXy #SITC25 #EndCancer

Great session exploring neuro-immunology in cancer immunotherapy #SITC25. Clearly we have much to learn about this little studied part of tumor biology. U Von Adrian demonstrated how afferent neurons organize and activate MDSCs at the tumor site @sitcancer.bsky.social

@kepauken.bsky.social, Sharpe et al. show that when PD-1–expressing and PD-1 knockout CD8+ T cells are within the same tumor microenvironment, both cell types exhibit similarly enhanced functions. rupress.org/jem/article/...

📘 #cancer #immunotherapy collection: rupress.org/jem/collecti...
#SITC25

Thank you for joining us as we took a step back in time and celebrated all we have accomplished in immuno-oncology over the past 40 years! #SITC25 Learn more here: https://www.sitcancer.org/2025/home

We had a successful Meet-the-Expert Lunch at #SITC25. Where early career scientists interacted and connected with experts in key areas of immunotherapy!

The Sparkathon program brought early career investigators to connect with established leaders in cancer immunotherapy at #SITC25! Special thanks to organizers @marcoruella.bsky.social and Jennifer Guerriero, PhD.

Ferry, Goldrath et al. show that differentiation of tissue-resident memory T cells (TRM) is accompanied by the upregulation of the conventional DC1 (cDC1) chemoattractant, Xcl1. rupress.org/jem/article/...

📘 In #cancer #immunotherapy collection: rupress.org/jem/collecti...
#SITC25

Excited to be attending my first SITC Annual Meeting! On Friday, Brandon Fischer from @nebanovich.bsky.social will present a poster on some of our work on Chlorotoxin CAR T cells. Check it out! #SITC25

Leading experts from the FDA and key stakeholders from industry and biotech discuss pressing topics in IO drug development. Biotech Regulatory Roundtable at #SITC25

Deng Pan lab report that an in vivo #CRISPR-Cas9 screen reveals that inactivation of Calreticulin (CALR) potentiates CD8⁺ T cell-mediated anti-tumor immunity and overcomes tumor immune evasion. rupress.org/jem/article/...

📘 In #cancer #immunotherapy collection: rupress.org/jem/collecti...
#SITC25

Chehyun Nam et al. uncover MLL3 mutations as early events driving UASCC development, highlighting their role in tumor evolution and immune modulation. rupress.org/jem/article/...

📘 In #cancer #immunotherapy collection: rupress.org/jem/collecti...
#SITC25

#SITC25 registration is open! Stop to grab your badge and explore our 40-year Timeline Walkthrough honoring the innovators and partners that supported us along the way!

Bernard A. Fox, Michael Geuenich, Catherine Phelps and other international investigators highlight groundbreaking IO advances during the 6th World Immunotherapy Council #SITC25